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AbstrAct
Introduction Environmental enteric dysfunction (EED) is 
a subacute inflammatory condition of the small intestinal 
mucosa with unclear aetiology that may account for 
more than 40% of all cases of stunting. Currently, there 
are no universally accepted protocols for the diagnosis, 
treatment and ultimately prevention of EED. The 
Bangladesh Environmental Enteric Dysfunction (BEED) 
study is designed to validate non-invasive biomarkers 
of EED with small intestinal biopsy, better understand 
disease pathogenesis and identify potential therapeutic 
targets for interventions designed to control EED and 
stunting.
Methods and analysis The BEED study is a community-
based intervention where participants are recruited from 
three cohorts: stunted children aged 12–18 months (length 
for age Z-score (LAZ) <−2), at risk of stunting children 
aged 12–18 months (LAZ <−1 to −2) and malnourished 
adults aged 18–45 years (body mass index <18.5 kg/
m2). After screening, participants eligible for study 
provide faecal, urine and plasma specimens to quantify 
the levels of candidate EED biomarkers before and after 
receiving a nutritional intervention. Participants who fail 
to respond to nutritional therapy are considered as the 
candidates for upper gastrointestinal endoscopy with 
biopsy. Histopathological scoring for EED will be performed 
on biopsies obtained from several locations within the 
proximal small intestine. Candidate EED biomarkers 
will be correlated with nutritional status, the results 
of histochemical and immunohistochemical analyses 
of epithelial and lamina propria cell populations, plus 
assessments of microbial community structure.
Ethics and dissemination Ethics approval was 
obtained in all participating institutes. Results of this 
study will be submitted for publication in peer-reviewed 
journals.
trial registration number  ClinicalTrials. gov ID: 
NCT02812615. Registered on 21 June 2016.
IntroductIon
Environmental enteric dysfunction (EED), 
previously known as tropical enteropathy 
and environmental enteropathy, is a subacute 
inflammatory condition of the small intes-
tinal mucosa with unclear aetiology. EED 
has been associated with a variety of envi-
ronmental exposures and host factors and 
is implicated in growth faltering.1 Linear 
growth faltering typically occurs within the 
first 2 years of life and after this period, it is 
difficult to reverse.2 Globally, there are more 
than 160 million stunted children (length for 
age Z-score (LAZ) <−2).3 Previous work in 
Gambia has revealed that 43% of observed 
growth faltering was associated with evidence 
of small intestinal enteropathy.4 There are 
no universally accepted protocols for the 
diagnosis and treatment of EED. The main 
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Protocol
strengths and limitations of this study
 ► This study will compare a wide array of non-
invasive biomarkers of environmental enteric 
dysfunction  (EED) to the diagnostic gold standard: 
intestinal histopathology.
 ► A histological scoring system will be developed for 
identifying EED and describing its severity.
 ► This study will be one of  the largest community-
based nutritional interventional studies in improving 
the growth parameters in children with stunting.
 ► Due to ethical reasons, collecting small intestinal 
tissue from healthy population of the same 
community will not be possible.
 ► ‘Failure to thrive’ criterion was selected based on 
assumptions as no data were available.
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Figure 1 Study design of Bangladesh Environmental Enteric Dysfunction study. GI, gastrointestinal.
impediments are a paucity of validated non-invasive 
biomarkers of small intestinal health, a lack of under-
standing of the pathologic state of the small intestine in 
EED and rudimentary knowledge of disease mechanisms.5 
While there are several candidate surrogate biomarkers 
of EED, to our knowledge none of these non-invasive 
biomarkers have been directly correlated with the diag-
nostic gold standard: intestinal histopathology. The 
Bangladesh Environmental Enteric Dysfunction (BEED) 
study, a community-based intervention study, is designed 
to validate candidate non-invasive biomarkers of EED and 
to identify potential therapeutic targets for interventions. 
This report describes the BEED study design, including 
the biospecimens and data types that are being collected 
for analyses.
MEthods And AnAlysIs
The protocol for the BEED study ( ClinicalTrials. gov 
identifier NCT02812615) was developed through a 
collaborative effort among International Centre for 
Diarrhoeal Disease Research, Bangladesh (icddr,b), 
Dhaka Medical College and Hospital (DMCH), Bang-
abandhu Sheikh Mujib Medical University (BSMMU), 
Dhaka, Dhaka Shishu Hospital, Dhaka, Apollo Hospi-
tals, Dhaka, Bangladesh, University of Virginia, USA 
and Washington University, USA. The study is funded by 
the Bill and Melinda Gates Foundation under its Global 
Health Program (http://www. gatesfoundation. org/ How- 
We- Work/ Quick- Links/ Grants- Database/ Grants/ 2015/ 
11/ OPP1136751). Enrolment has been initiated and is 
expected to continue until December 2018.
objectives
The goals of this study are to (1) develop a histological 
scoring system for identifying EED and describing its 
severity; (2) employ this scoring system to test the validity 
of proposed, candidate non-invasive biomarkers of EED 
and identify novel biomarkers; (3) test the degree of 
correlation between EED score and nutritional status 
defined by anthropometry; (4) determine the role of 
the gut microbiota in the pathogenesis of EED, in part 
through transplantation of luminal/mucosal proximal 
small intestinal and faecal microbiota from malnour-
ished children with and without histopathological 
evidence of EED into gnotobiotic mice to directly 
test transmissibility of gut barrier/mucosal immune, 
growth and metabolic phenotypes and (5) characterise 
biological pathways that operate in the host and/or 
gut microbiota that are associated with EED to identify 
potential therapeutic targets.
study settings and participants
The overall design of the BEED study is illustrated in 
figure 1. There is a community-based nutrition inter-
vention group and a comparison group. In the nutrition 
intervention group, participants are being recruited 
from two age groups: a child cohort (age 12–18 months) 
and an adult cohort (age 18–45 years). The child cohort 
consists of individuals who are stunted (LAZ <−2) and 
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Table 1 Nutrition and health interventions
Intervention Delivery method
Egg One egg daily, 6 days a week for either 
2 months (children at risk for stunting and 
malnourished adults) or 3 months (stunted 
children)
Milk 150 mL whole milk daily, 6 days a week for 
either 2 months (children at risk for stunting 




–Parents will be given one sachet of 
multiple micronutrient sprinkles per day to 
be administered to the child at home with 
the midday meal for 2 months
–Each sachet contains one recommended 
dietary allowance (RDA) of vitamin A, 
vitamin C, folic acid, iron and zinc
Nutritional 
counselling
Parents/caregivers will be provided with 
nutritional counselling with particular 
emphasis on adding vegetable oil to the 
cooked diet as a source of energy as well 
as sources of animal-based products, such 
as small fish or chicken meat, and so on 
along with regular intake of vegetables
Antihelminthic 
treatment
–As per national guidelines
–If participants have not been treated for 
helminths in the preceding 3 months, will 
get either 200 mg of albendazole or 10 mg/
kg pyrantel pamoate single dose
Treatment Intercurrent illnesses
those who are at risk of stunting (LAZ <−1 to −2). These 
two subgroups will be used to compare histopatholog-
ical features of EED with LAZ scores. The adult cohort 
consists of malnourished individuals (body mass index 
(BMI) <18.5 kg/m2) who will provide an opportunity to 
further explore the association between body mass (in 
this case low BMI) and the pathological features of EED 
and also critically assess the degree to which histopatho-
logical features of EED in children manifest in adults.
The BEED study is recruiting two control groups 
in order to compare the histological features in their 
duodenal mucosal biopsies with those of documented 
in cases of EED. Due to obvious ethical considerations, 
it is not possible to collect small intestinal biopsy samples 
from entirely healthy and asymptomatic subjects. There-
fore, biopsies are being collected from children who 
are neither stunted nor suffering from EED and who 
undergo upper gastrointestinal (UGI) endoscopy as part 
of their clinical care. This control group of children are 
being recruited by the collaborators at the University of 
Virginia Hospital in Charlottesville, Virginia, USA. An 
equal number of age-matched and sex-matched healthy 
adult controls (BMI >18.5) suffering from functional 
dyspepsia who have no evidence of any organic diseases 
are being recruited from the Gastroenterology Outpatient 
Department of DMCH and the icddr,b Staff Clinic and 
undergo UGI endoscopy.
Following application of the inclusion/exclusion 
criteria listed in online supplementary file 1, undernour-
ished children and adults are receiving nutrition and 
health interventions (table 1). Participants who fail to 
respond to nutritional therapy are considered eligible 
for UGI endoscopy with mucosal biopsies. Candidate 
EED biomarkers are being measured in faeces, urine and 
plasma samples collected from participants once before 
and once after the nutritional intervention.
The BEED study is conducted among residents of 
Mirpur, one of the 21 administrative units of the nation’s 
capital, Dhaka. The Mirpur area is located 7–8 km from 
the icddr,b Dhaka Hospital at Mohakhali. Mirpur has 
a population of ~500 000 living in an area of 14.22 km2: 
that is, the population density is more than 38 000 people 
per square kilometre. The detailed socioeconomic and 
demographic information of the study location has been 
published elsewhere.6
sample size
Participants are being recruited in a cross-sectional 
manner. Sample size calculations were predicted on 
the following assumptions: prevalence of stunting at 
our study site is 40%; after receiving nutrition interven-
tion ~20% will fail to manifest improved linear growth; 
only one-third will give their consent for endoscopy 
and 90% of the stunted children will have one or more 
abnormal gut biomarkers with a precision of 10% and 
95% CI. Using the formula n=(Z1−α/2)
2×P×(1−P)/d2, 
where n is the required sample size without attrition; P is 
the prevalence of one or more abnormal gut biomarker in 
stunted children=90% or 0.9; d is the level of actual preci-
sion=10% or 0.1; Z1−α/2 is the value for standard normal 
distribution at 95% level of significance=1.96, a minimum 
of 35 stunted children, 35 children at risk of stunting and 
35 malnourished adults will be needed for UGI endos-
copy and biopsy. Therefore, the final sample size for 
endoscopy is 105 subjects (35+35+35). As endoscopy is 
an invasive procedure, we assume that only one-third of 
those who will fail to respond after nutrition intervention 
will give consent for the procedure. As a consequence, 
the ‘basic’ sample size was increased threefold for a 
minimum of 105 (35×3) stunted children, 105 (35×3) 
children at risk of stunting and 105 (35×3) malnourished 
adults. To achieve this goal, 525 stunted children, 525 
children at risk of stunting and 525 malnourished adults 
will be recruited for nutrition interventions, based on the 
assumption that ~20% of each group will fail to respond 
despite the nutritional intervention. To enrol the desired 
numbers of participants, at least 3977 (1312+2665) chil-
dren 12–18 months old and 2100 adults needed to be 
surveyed based on the current prevalence of malnutri-
tion in both the age groups. An equal number (35) of 
age-matched and sex-matched apparently healthy adult 
controls (BMI >18.5) will be recruited from the outpa-
tient department of DMCH and icddr,b Staff Clinic. Apart 
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from the dyspeptic symptoms by Rome III criteria,7 these 
subjects will have no other symptoms.
dietary supplementation
Supplementation (table 1) of the usual home diet with 
one boiled egg and 150 mL of whole milk provide an 
additional 745 kilojoules, 11.1 g of protein and 11.5 g 
of fat to the daily diet of enrolled subjects. The duration 
of the intervention is 3 months for the stunted cohort 
and 2 months for those who are at risk for stunting and 
malnourished adults. Egg and milk were selected consid-
ering the nutritional values and the fact that they have 
shown acceptable to the target population in a small pilot 
study. Multiple studies have found significant positive 
effects of egg and milk on linear growth.8–10
Nutritional therapy is delivered between the morning 
and midday meal, anytime between 10:00 am to 11:30 am 
to avoid the food substitution. Participants are asked to 
come to the designated nutrition centre daily for their 
nutritional therapy in order to avoid the issue of food 
sharing with other family members. A staff member visits 
the family’s household if a participant defaults in coming 
to the nutrition centre. Study co-investigators also visit 
nutrition centres regularly to monitor food left over, 
absenteeism and other issues of compliance.
We assume that this regimen of food supplementation 
plus counselling will result in incremental improvement 
in linear growth of participant children. A participant is 
discontinued from the study and referred for medical 
evaluation if he/she shows reluctance to feed for 7 
consecutive days, which includes daily intake of ≤50% of 
the offered food.
collection, preparation and archiving of biological samples
All biological samples (blood, urine, stool, breath, 
duodenal aspirates and endoscopic biopsies) are 
collected, prepared and preserved (see online supple-
mentary file 2) as per the standard operating procedures 
(SOPs) prepared for this protocol.
Breath samples are being collected for testing of small 
intestinal bacterial overgrowth (SIBO). The first SIBO 
test is performed before the nutrition intervention 
and a second SIBO test is done 1–2 weeks prior to the 
endoscopy, so that findings from the endoscopy can be 
compared with results obtained from the hydrogen breath 
tests. QuinTron Breath tracker machine and associated 
QuinTron accessories are used for sample collection and 
analysis.11
Faecal samples are collected and cryopreserved within 
20 min of production. At the site of collection, samples 
are aliquoted into sterile, prelabelled 2 mL cryophials 
and immediately placed into precharged liquid nitrogen 
dry cryo-shippers for transport back to the laboratory 
where they are transferred into a −80°C freezer prior to 
shipping. No additives, preservatives or media is added 
to the faecal samples. Culture-independent as well as 
culture-based analyses of the faecal microbiota (micro-
bial community samples obtained from the UGI tract at 
the time of endoscopy) will be performed at Washington 
University in St. Louis, USA.
All other samples for biomarker assessment are carried 
to the laboratory using cool box and cool packs. For 
blood samples, with all aseptic precautions 5 mL venous 
blood is collected in a blood collection tube (S-Mon-
ovette 7.5 mL, Sarstedt) and transported to laboratory. 
Initially, 0.5 mL blood is transferred into a centrifuge tube 
and the remaining 4.5 mL is centrifuged for the separa-
tion of plasma. The plasma is then aliquoted and stored 
at −80°C. Chlorhexidine is added to urine samples as a 
preservative. All the samples from each individual are 
collected within a 3–4 days window period.
biomarkers
A wide array of biomarkers of enteropathy will be tested 
in the BEED study. A list of candidate biomarkers was 
prepared after a thorough literature review and analysis of 
data emanating from the Etiology, Risk Factors and Inter-
actions of Enteric Infections and Malnutrition and the 
Consequences for Child Health and Development (MAL-
ED)12–14 and Performance of Rotavirus and Oral Polio 
Vaccines in Developing Countries (PROVIDE)15 studies 
(table 2).
Indications for and details of the procedures used for uGI tract 
endoscopy and mucosal biopsy
After completion of nutritional therapy, all enrolled 
participants are assessed for responses. Definitions of 
‘failure to thrive/respond’ are as follows:
 ► LAZ score remains <−2 for members of the stunted 
children cohort
 ► LAZ score remains <−1 for the ‘at risk of stunting’ 
children cohort
 ► BMI <18.5 kg/m2 and <10% increase in BMI for those 
in the adult cohort
Participants who meet the study definition of ‘failure to 
thrive/respond’ are further checked for the presence of 
any secondary cause of malnutrition such as tuberculosis, 
any parasitic infection, and so on. If nothing conclusive is 
found, the participant may undergo preparations for UGI 
endoscopy with biopsy. Participants with celiac disease 
(as defined by tissue transglutaminase IgA, and clotting 
disorders (determined by prothrombin time/Interna-
tional normalised ratio (INR) coagulopathy tests) will be 
excluded from the study. There is no published informa-
tion about the prevalence of celiac disease in Bangladesh 
from any representative sample.16 One study of hospital-
ised adult patients with irritable bowel syndrome observed 
that the prevalence of celiac disease was 9%.17 In the 
BEED study, immediate test results for celiac disease are 
not available; therefore, we are unable to screen out indi-
viduals with this disorder before nutrition intervention 
is initiated. Nonetheless, BEED will screen 1575 partici-
pants for celiac disease; as such, it will be the first study 
in Bangladesh to explore the prevalence of this disorder 
in a paediatric population. Necessary management and 
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Table 2 Summary table for non-invasive biomarker candidates and related processes
Process of gut health Biospecimen Non-invasive biomarkers
Epithelial health and repair Faeces Reg1B
Intestinal barrier dysfunction and 
bacterial translocation
Blood and urine Alpha-1-antitrypsin, lactulose/rhamnose ratio
Intestinal inflammation Faeces Myeloperoxidase, neopterin, calprotectin
Systemic inflammation Blood sCD14, CRP, AGP, KT ratio
Epigenetic metabolomes Blood LRP1
Enteric infection Faeces, breath sample TaqMan Array Card, SIBO
Nutrient malabsorption Blood Ferritin, zinc, GLP-2, pepsinogen I/II ratio
Celiac Disease screening Blood IgA tissue transglutaminase, total IgA
AGP, alpha 1-glycoprotein; CRP, C reactive protein; KT ratio, kynurenine/tryptophan ratio; LRP1, low density lipoprotein receptor-related 
protein 1; GLP-2, glucagon-like peptide-2; Reg1B, regenerating family member 1 beta proteins; sCD14, soluble cluster of differentiation 14; 
SIBO, small intestinal bacterial overgrowth.
counselling is provided to the participants suffering from 
celiac disease or clotting disorders.
Endoscopy of the UGI tract is performed as per stan-
dards recommended by North American Society for 
Pediatric Gastroenterology, Hepatology and Nutrition, 
the American College of Gastroenterology and the Amer-
ican Society for Gastrointestinal Endoscopy (ASGE).18 
The procedure is generally scheduled in the early 
morning after fasting from midnight. Gastroenterolo-
gists, who perform endoscopy, discuss with the subjects 
and their guardians regarding the indication of the 
procedure, the sedation plan, the risks associated with 
sedation and describe the total procedure, likely benefits, 
common adverse events (AEs), alternatives to the proce-
dure and the prognosis of the subjects if endoscopy is 
declined. After this discussion and proper counselling, the 
gastroenterologists personally obtain consent from the 
subjects on the day of the procedure. A separate consent 
is obtained for sedation. A preprocedure assessment that 
includes medical history and physical examination is also 
completed by the gastroenterologist himself.
Once the preprocedure assessment is completed and 
no concerns are identified by the gastroenterologist, the 
subject is proceeded to the endoscopy room. A quali-
fied anaesthetist attends the procedure to assess and 
administer the steps, as required, for sedation. Before 
sedation is administered, the intended level of sedation 
is graded (nil, minimal, moderate and deep sedation 
or general anaesthesia) as per the recent guidelines of 
ASGE.18 19 Children are sedated using general anaesthesia 
by an expert and qualified anaesthetist. UGI endoscopies 
of adult participants are performed under conscious 
sedation using midazolam. The oropharynx is anaesthe-
tised with 10% lidocaine spray; concomitantly, midazolam 
(3–5 mg) is injected intravenously to induce conscious 
sedation.19
The endoscopic procedure is performed with a goal 
of collecting up to six biopsies from each child and up 
to eight biopsy samples from each adult participant. As 
per the protocol, one biopsy is taken from the duodenal 
bulb; the rest of the biopsies are collected from the distal 
part of the duodenum. Duodenal fluid is aspirated for 
culture-independent and culture-based assessments of 
the composition of the proximal small intestinal micro-
bial community and for assays of host and microbial 
products. Secretions are rapidly aspirated first from the 
second portion of the duodenum using sterile Endo-
scopic Retrograde Cholangiopancreatography (ERCP) 
catheters. Following this initial aspiration, the postbulbar 
mucosa is irrigated with a maximum of 25 mL of sterile 
0.9% normal saline, and the lumen contents are aspi-
rated through the ERCP catheter. The lavaged aspirates 
are aliquoted and processed as per the SOP described in 
table 3.
Participant undergoing endoscopy is observed in the 
postprocedure recovery room until he/she meets prede-
termined standard discharge criteria.20 The subjects who 
undergo the endoscopy procedure are followed up for 
14 days after the procedure to determine whether any 
AEs have occurred after discharging from the endoscopy 
unit and whether these are attributable to the procedure. 
An appropriate course of action will be followed if such 
events occur; the cost of management of all postproce-
dure complications will be borne by the study. Participants 
receive appropriate treatment based on the results of 
reports from the endoscopy and biopsy procedure. As 
for example, participants diagnosed endoscopically with 
antral gastritis are screened for Helicobacter pylori and 
prescribed proper treatment, as per standard recommen-
dations.
Protocol timeline
The overall schedule for enrolment, interventions and 
assessments, including UGI endoscopy and biopsies, is 
described in table 4.
data collection, management and storage
Data collection tools for this study include case report 
forms, laboratory worksheets and source documen-
tation. Complete source documentation (study visits, 
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Table 3 Biopsy specimen processing
Specimen Recipient fluid Processing Purpose
Biopsy #1 RNAlater Nucleic acid extraction Transcriptomics
Biopsy #2 HBSS FACS Cell isolation
Biopsy #3 None Flash frozen Culture-independent and culture-based assays 
of mucosa-associated microbial community
Biopsy #4 None Flash frozen Archiving for validation of drug targets
Biopsies #5 and #6* Formalin Paraffin embedded Histochemistry (H&E) and 
immunohistochemistry;
Morphometric analyses and EED scoring
Duodenal Aspirate Microbiota: glycerol/
cysteine solution
Other: Nil
Precharged N2 dry 
shipper to −80 freezer
Culture-independent and culture-based assays
*Biopsy site: biopsy #6 from duodenal bulb, all others distal to the ampulla of Vater.
EED, environmental enteric dysfunction; FACS, fluorescence-activated cell sorting; HBSS, Hank’s balanced salt solution.
laboratory reports, and so on) is done for each partici-
pant in individual study charts. All laboratory specimens, 
reports, study data collection and administrative forms 
are identified by coded number to maintain participant 
confidentiality and to enable tracking throughout the 
study. Bar-coded labels are used for all laboratory speci-
mens. All information regarding study subjects are kept 
in password-protected computer files, or in locked file 
cabinets that can be accessed only by authorised study 
personnel. Anthropometric data (table 4) are collected 
twice in a month. The total amounts of food offered, 
consumed and leftover are recorded. All foods are 
weighed with precision scales (see online supplementary 
file 3). Multiple food frequency data are collected from 
all the participants, whereas a 24 hours dietary recall data 
are being collected from a subgroup of randomly selected 
children as well as adults (50 in each group) to assess their 
food habits and food substitution, if any.
data analysis plan
This study will yield a rich dataset containing socio-demo-
graphic and anthropometric information, food security 
status, plus faecal, urine, plasma and breath associated 
biomarkers, the results of histopathological measure-
ments as well as data related to small intestinal gut 
health risk factors. After evaluation of biopsy specimens, 
a pathologist will assign a histopathological grade, in a 
blinded fashion, based on histological changes deemed to 
be signatures of EED: these include changes in mucosal 
architecture (shortening of the villi, increase in the depth 
of the crypts), changes in immune-inflammatory cell 
content (lymphocytic infiltration into the lamina propria 
and epithelium) and changes in epithelial features 
(goblet cell content, evidence of enterocyte injury and so 
on).21 Statistical tests of correlations between histopatho-
logical scores, biomarker levels and anthropometric 
changes will be performed. An ‘inter-group’ comparison 
(stunted children vs children at risk of stunting; stunted vs 
non-stunted, and so on) will be performed for validation 
of histopathological grading. The analysis plan includes 
relatively simple linear modelling of all continuous and 
dichotomous measures to establish whether biomarkers 
are associated with anthropological changes or not. 
Biomarkers exhibiting statistically significant changes will 
be identified and their final validation will be performed 
by comparing their levels with histopathological changes.
An important research question is whether enteric 
infections, and gut immune responses to those infections, 
are associated. While preliminary inferences of linkage 
are possible from a careful interpretation of simple 
univariate and bivariate analyses, instrumental variable 
analysis (for the control of unmeasured covariates) will 
also be performed.
Being an invasive procedure requiring hospitalisation, 
histopathological diagnosis of EED will not be possible as 
a routine approach in at-risk populations in low-income 
settings. A goal of this project is to validate surrogate 
biomarkers of the disease and use these for developing 
models to predict future negative histopathological and 
clinical outcomes. From a list of significant biomarker 
variables, we will select a ‘best’ subset by using a branch 
and bound algorithm. This method will test all biomarker 
subsets in contrast to the more usual forward or reverse 
stepwise regression. As development of prediction model 
risks over-fitting to the data set, we plan to partition the 
data set into model training (2/3) and test (1/3) subsets, 
using the test set at the end of the fitting to establish an 
unbiased estimate of the generalisation error. We will 
estimate the prediction error in the training set using 
cross-validation methods. A subset model of biomarkers 
will also be used to create a composite score of EED.
Monitoring and quality control measures
We are using previously established and validated SOPs 
for data collection, monitoring and quality control 
measures.12 22 A field supervisor re-collects 10% of all 
collected data, including anthropometry and dietary 
assessments. Monitoring reports are prepared weekly. 
An Excel-based program is used for scheduling data and 
sample collection from each participant. All activities 
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of the BEED study are being performed according to 
a Manual of Procedures (a collection of all SOPs). A 
summary of quality control measures is described in 
online supplementary file 4.
challenges
Several questions arose in the development and imple-
mentation of the BEED study, all of which were brought 
to the Investigators’ Committee for discussion and resolu-
tion. For example, AEs that may arise during endoscopy 
were a big concern and to solve the issues, investigators 
have developed a priori definitions, assessment criteria 
and action guidelines. Morbidity and poor appetite also 
represent a big challenge; by providing proper counsel-
ling and by practising supportive feeding techniques, this 
issue can be resolved.
EthIcs And dIssEMInAtIon
Ethical approvals
Ethical approvals were obtained from Research Review 
Committee (RRC) and Ethical Review Committee (ERC) 
of icddr,b (protocol no: PR-16007; Version 1.03; March 1, 
2016), the Ethical Committee of Dhaka Medical College 
(DMC/ ECC/2016/39). Institutional Review Board for 
Health Sciences Research (IRB-HSR) of University of 
Virginia, Charlottesville, the Human Research Protection 
Office (HRPO) of Washington University in St. Louis (the 
latter for analyses of collected biospecimens).
consent
Each participant enrolled in BEED study is treated 
according to what is morally right and proper. Separate 
consent forms are being used for children and adult 
participants. After complete disclosure, a signed informed 
consent statement is obtained from each subject. For 
minors, informed consent is obtained from the parents or 
authorised legal guardian of the subject. The consenting 
process takes place, preferably, in the residence of the 
subject. If the subject or the parent(s)/guardian agree 
to participate in the study, they sign the consent form or 
provide an impression of their left thumb. The investi-
gator and a witness also sign the form. For endoscopy, a 
separate consent form is used and the aforementioned 
procedure is followed. The consent form for endoscopy 
clearly and fully describes, and demystifies, all aspects of 
the process, including the risks related with the proce-
dure. No information is remained withheld from the 
participant.
Adverse events
Expected AEs for this protocol are those related to the 
endoscopy/biopsy procedure that do not qualify as a 
serious adverse event (SAE) and those associated with 
phlebotomy and ingestion of lactulose/rhamnose solu-
tion. Both serious and non-SAEs are assessed for their 
severity, their relationship to study participation and the 
actions taken and their outcomes. All SAEs are being 
reported to the ERC of icddr,b within 24 hours of the 
site’s awareness of the event. In the event that medical 
care is required outside of the protocol, all necessary and 
available treatments are provided, free of cost.
safety issues for uGI endoscopy and biopsy
Although never without elements of risk during the 
procedure and anaesthesia, endoscopy is a safe procedure 
when conducted by trained experienced personnel in a 
well-equipped facility. In Gambia, a study was done where 
40 children were recruited and underwent endoscopy 
under intravenous sedation.23 In the University Teaching 
Hospital, Lusaka, Zambia, investigators collected duodenal 
biopsy samples via endoscopy under sedation with midaz-
olam from 41 malnourished children to compare their 
inflammatory status with normal children.24 Neither of 
these studies reported any endoscopy-related AEs during 
or after the procedures. Following standard recom-
mendations and guidelines, endoscopic procedures are 
performed by members of a team of co-investigators 
consisting of experienced consultant gastroenterolo-
gists from BSMMU, DMCH, Apollo Hospital, Dhaka and 
icddr,b. A qualified anaesthetist attends the procedure 
to assess and administer steps as required for sedation. 
The participant’s oxygen saturation level, pulse rate and 
blood pressure are continuously monitored throughout 
the procedure. Resuscitation measures and complete ICU 
support remain available during the procedure for imme-
diate resuscitation if necessary. Clinical findings from the 
biopsies (eg, presence of gastritis) are made available 
quickly so that appropriate treatment can be undertaken 
in a timely manner.
dissemination and publication
The data, results and other findings resulting from this 
study will be published only after approval by a committee 
consisting of the investigators of the protocol. The Inter-
national Committee of Medical Journal Editors guidelines 
will be used to establish authorship on papers.
Project status
As of May 2017, participant enrolment is ongoing.
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